ripasudil

Trade name: Glanatec

Small moleculeexperimental

Ripasudil, a derivative of fasudil, is a rho kinase inhibitor drug used for the treatment of glaucoma and ocular hypertension. — Wikipedia

Clinical trial activity

12 trials · 19 clinical orgs · 0 marketing orgs

Phase 1
2
Phase 2
10
Phase 3
7
Phase 4
1

Earliest trial started Dec 6, 2017 (NCT03249337)

Timeline

2010s

  1. Jan 1, 2018

    Earliest Phase 2 Sponsor(trial)

2020s

  1. Jan 1, 2020

    Earliest Phase 1 Sponsor(trial)

  2. Jan 1, 2020

    Earliest Phase 3 Sponsor(trial)

Indications

Approved for

Mechanism of action

Chemistry & pharmacology

Loading structure…

SMILES

C[C@H]1CNCCCN1S(=O)(=O)c1cccc2cncc(F)c12
Mol. weight
323.39 g/mol
Lipinski Ro5
Pass
Rule of 3
No
Chirality
Single Stereoisomer
Inorganic
No
Polymer
No

Oral

No

Parenteral

No

Topical

No

Sources

Also known as

  • glanatec
  • glanatec ophthalmic solution
  • ripasudil
  • ripasudil
  • ripasudil
  • ripasudil
  • ripasudil
  • ripasudil hcl
  • ripasudil hydrochloride
  • ripasudil hydrochloride hydrate

Clinical trials

NCT IDPhaseStart dateSponsor(s)
NCT06048380Phase 3Oct 31, 2023Singapore Eye Research Institute
NCT05826353Phase 3May 11, 2023Kowa
NCT05795699Phase 3Mar 30, 2023Kowa
NCT05636579Phase 1Dec 1, 2022Asociación para Evitar la Ceguera en México, Emmecell
NCT05528172Phase 3Aug 4, 2022Kowa
NCT05289661Phase 3Jul 15, 2022Case Western Reserve University, Dartmouth University, Oregon Health and Science University, Stanford University, University of California, Davis, University of California, San Francisco, University of Pennsylvania
NCT05275972Phase 3Jul 15, 2022Case Western Reserve University, Dartmouth University, Oregon Health and Science University, Stanford University, University of California, Davis, University of California, San Francisco, University of Pennsylvania
NCT04620135Phase 3Nov 12, 2020Aerie Pharmaceuticals
NCT04621136Phase 1/Phase 2 (Phase 2)Nov 1, 2020Kyushu University
NCT03813056Phase 2Mar 1, 2019Eye Bank Association of America, Legacy Devers Eye Institute, Legacy Health System, Lions Clubs International Foundation (funding)
NCT03575130Phase 2Jun 5, 2018University of Erlangen-Nuremberg
NCT03249337Phase 4Dec 6, 2017University of Chicago
Showing 12 of 12 trials
Page 1 / 1

Organizations

Research & Development (19)

OrganizationOrg typeTrialsAs lead sponsorPhasesEarliest year
KowaFor profit3312022
Case Western Reserve UniversityAcademic/Hospital2012022
Dartmouth UniversityAcademic/Hospital2012022
Oregon Health and Science UniversityAcademic/Hospital2012022
Stanford UniversityAcademic/Hospital2212022
University of California, DavisAcademic/Hospital2012022
University of California, San FranciscoAcademic/Hospital2012022
University of PennsylvaniaAcademic/Hospital2012022
Aerie PharmaceuticalsFor profit1112020
Asociación para Evitar la Ceguera en MéxicoAcademic/Hospital1112022
EmmecellFor profit1012022
Eye Bank Association of AmericaAcademic/Hospital1012019
Kyushu UniversityAcademic/Hospital1112020
Legacy Devers Eye InstituteAcademic/Hospital1012019
Legacy Health SystemAcademic/Hospital1112019
Lions Clubs International Foundation (funding)Academic/Hospital1012019
Singapore Eye Research InstituteAcademic/Hospital1112023
University of ChicagoAcademic/Hospital1112017
University of Erlangen-NurembergAcademic/Hospital1112018
19 organizations
Page 1 / 1